Home | Coverage | Agents | Pulse | LogIn |
| Darwin Score | +7 |
| Ticker | CUV |
| Latest Price | 10.16 AUD as of close on 04-Jul-2025 |
| 3 Month price range | 9.44 to 11.63 AUD |
| Market Capitalisation | 509.76Mn AUD |
| Country | Australia |
| Region | Asia |
| Economic Sector | Health Care |
| Business Sector | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Sub-Industry | Biotechnology |
| Description | Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone to produce cortisol and enables the combat of stress and regulation of immune responses, maintenance of blood pressure, moderation of blood sugar, and regulation of metabolism. The company was incorporated in 1999 and is headquartered in Melbourne, Australia. See More ... |
| Company URL | https://www.clinuvel.com |
| See Darwins Full Analysis for Clinuvel Pharmaceuticals Ltd |
Tell Me About (TMA) is Darwins structured scoring system for assets. Here are the scores from the key TMA sections for Clinuvel Pharmaceuticals Ltd. Further information and full detail is available when you login.
| TMA Part | Focus of Analysis | TMA Score |
|---|---|---|
| Price | Analysis of performance, trend, RSI, OBV and moving averages | -4 |
| Sentiment | News and Candle Patterns. | 0 |
| Fundamentals | Analyst Ratings, Valuation and Dividend analysis. | +4 |
| Flow | Institutional, Fund and Insider buying and selling. | 0 |
| Models | Forecast models. | +7 |
There are 3 live alerts for Clinuvel Pharmaceuticals Ltd.
There are 12 peers of Clinuvel Pharmaceuticals Ltd.
| Asset Name | Industry Group | Perf(20d)% | Asset Score |
|---|---|---|---|
| Argenica Therapeutics Ltd (AGN) | Biotechnology | -2.0 | +22 |
| Arovella Therapeutics Ltd (ALA) | Biotechnology | +19.2 | +2 |
| CSL Ltd (CSL) | Biotechnology | -2.1 | +19 |
| Imugene Ltd (IMU) | Biotechnology | -23.7 | -9 |
| Mesoblast Ltd (MSB) | Biotechnology | -7.9 | -10 |
| Opthea Ltd (OPT) | Biotechnology | 0 | -12 |
| PYC Therapeutics Ltd (PYC) | Biotechnology | +9.1 | +24 |
| Paradigm Biopharmaceuticals Ltd (PAR) | Biotechnology | +49.2 | +18 |
| Polynovo Ltd (PNV) | Biotechnology | -9.1 | +2 |
| Race Oncology Ltd (RAC) | Biotechnology | -0.4 | -9 |
| Telix Pharmaceuticals Ltd (TLX) | Biotechnology | -11.9 | +7 |
| Tissue Repair Ltd (TRP) | Biotechnology | +16.2 | -10 |
To see complete information on Clinuvel Pharmaceuticals Ltd or any other assets please login.
If you do not already have an account you can register for a free trial of our service. This will let you explore all the analytical information we have on price, fundamantals, flow, sentiments & models for all the stocks under coverage. You will then be able to compare asset scores and perform a wide range of multi asset analysis such as Market Cycles and Relative Scores.
Follow Us | |
©2025 Darwin Knows - All Rights Reserved | |